SLC16A3 and breast cancer: Analyzing all tumor subtypes together suggested that the alterations in expression of glycolytic (SLC16A3)- and mitochondrial (GFM2)-associated genes may be a general feature of aggressive breast cancers (Additional file 1: Fig S1C, D).